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Introduction. Large trials have shown that angiotensin converting enzyme inhibitor (ACE-I) therapy reduces the risk of
myocardial infarction and stroke. Acute vascular events are thought to be initiated by plaque rupture. Animal models of
atherosclerosis show an increase in extra cellular matrix when given ACE-I therapy. ACE-I therapy could influence collagen
synthesis, one of the major constituents of the atherosclerotic cap.
Methods. A nested case-control study was performed within the Huntingdon Aneurysm Screening Project. Subjects were
assessed for arterial disease, drug history and smoking. Blood samples were taken for a measure of collagen synthesis, the
amino-terminal propeptide of type III procollagen (PIIINP), lipid levels, iron metabolism and cotinine levels.
Results. Information was available for 420 subjects. Thirty-five were taking ACE-I therapy and 385 were not. Mean serum
PIIINP level was 3.5 mg/l (sd 1.3 mg/l, range: 1.7–16.5 mg/l. There was a marked increase in mean collagen turnover
between subjects taking ACE-I therapy compared to those not. Mean PIIINP level for cases and controls was 4.26 mg/l (95%
CI: 3.73–4.79 mg/l) versus 3.61 mg/l (95% CI: 3.48–3.75 mg/l). No differences were found for patients taking other
antihypertensive drugs. After adjusting for age, weight, height, lipid levels and ferritin, PIIINP levels remained significantly
higher in cases than controls: 4.14 mg/l (95% CI: 3.72–4.57 mg/l) versus 3.62 mg/l (95% CI: 3.49–3.75 mg/l) (P-value
0.02).
Discussion. These results suggest that ACE-I therapy up-regulates collagen synthesis, and could improve plaque
stabilisation. This may provide an explanation for the decrease in acute vascular events observed in patients on ACE-I
therapy.
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Introduction
Several large trials have shown that treatment with
ACE inhibitors significantly reduces the risk of
myocardial infarction and stroke. This effect was
demonstrated to be independent of reduction in
blood pressure and concomitant medication.1 It is
thought that most acute vascular events begin with
rupture of an atherosclerotic plaque. This suggests
that ACE inhibitors lower the risk of atherosclerotic
plaque rupture.
Unstable plaques, at higher risk of rupture, tend to
have a thin, friable fibrous cap. The cap consists of
extra cellular matrix, the chief component of which is
collagen. Type I and III are the major structural
components that confer tensile strength to the fibrous
cap.2,3 Type III is also the major component of large
arteries, muscle and skin.4,5 Collagen homeostasis is
determined by the opposing metabolic processes of
collagen synthesis and collagen degradation. A large
amount of research has implicated increased matrix
metalloproteinase (MMP) activity as an important
factor in increased collagen degradation.6–8 However,
it is important to consider increased collagen synthesis
as well. This study was performed to investigate an
effect of ACE inhibitors on collagen type III synthesis.
Methods
A screening programme for asymptomatic abdominal
aortic aneurysms in males over the age of 50 started in
Huntingdon, England in November 1991. The cohort
of screened men over the age of 50 living in the
Eur J Vasc Endovasc Surg 28, 67–70 (2004)
doi: 10.1016/j.ejvs.2004.01.021, available online at http://www.sciencedirect.com on
*Corresponding author. Dr A. B. M. Wilmink, Senior Lecturer in
Vascular Surgery, University of Birmingham, Birmingham
HeartlandsHospital, Bordesley Green East, BirminghamB9 5SS, UK.
1078–5884/010067+ 04 $35.00/0 q 2004 Elsevier Ltd. All rights reserved.
Huntingdon District served as a basis for this study.
All subjects underwent informed consent, and ethical
approval was gained locally. All subjects were inter-
viewed about their family history, previous medical
history, drug history, and smoking habits. All subjects
had a brief medical examination by the same observer.
The medical examination included measurement of
the ankle brachial pressure index (ABPI) and the aortic
diameter by ultrasound. Peripheral arterial occlusive
disease (PAOD) was deemed present if the ABPI was
less than 0.9. An aneurysm was defined as an
infrarenal aortic diameter of 3 cm or more.
A blood sample was taken from all patients for
measurement of serum collagen turnover, lipid levels,
markers of iron metabolism and cotinine levels.
Smoking and cholesterol are standard risk factors for
atherosclerotic disease and acute vascular events.
Therefore measurements of serum cotinine levels
and lipid levels allowed us to adjust for possible
differences in the distribution of those risk factors
between the groups exposed to ACE inhibitors and
those not exposed. Markers of iron metabolism were
measured as iron is an important cofactor in collagen
metabolism.4,5 These markers consisted of serum iron,
transferrin, ferritin and antichymotrypsine levels.
Blood samples were taken at the time of the medical
examination. They were spun down and the serum
frozen at 221 8C on the same day for analysis later.
Batches of 74 serum samples were analysed in
duplicate on the same day, by the same biochemist
from the Department of Chemical Pathology in
Hinchingbrooke Hospital. The concentration of the
amino-terminal propeptide of type III procollagen
(PIIINP) was used as a proxy measure of type III
collagen turnover. The amino-terminal propeptide is
split from the procollagen molecule during type III
collagen synthesis.4,5 The concentration of PIIINP was
measured using an equilibrium type serum radio-
immunoassay for the amino-terminal propeptide of
type III procollagen. This was based on highly purified
specific human antigen (Pharmacia & Upjohn Ltd,
Diagnostics Division, Milton Keynes, UK) and per-
formed according to the instructions of the manufac-
turer with the use of duplicate 200 ml aliquots of
serum.9,10 The assay detects the authentic amino-
terminal propeptide of type III collagen, but is not
sensitive to the smaller degradation products of the
propeptide.9 The antigens are resistant to repeated
thawing and freezing.10 The benefit of this assay is that
standard and human serum samples give parallel
inhibition curves allowing more accurate reading of
serum levels without the need for repeated dilution
and analysis.9 The intra-assay and inter-assay coeffi-
cients of variation of this assay are less than 5% and the
sensitivity is 0.2 mg/l. The reference range for adults,
based on data of Finnish blood donors was 1.7–
4.2 mg/l, with no differences between males and
females.9 The lipid profile consisting of serum total
cholesterol, HDL cholesterol, LDL cholesterol and
triglycerides was determined using an automated
procedure on a random blood sample. Blood samples
were taken during clinic attendance. Screening clinics
were in the evening at 5 pm or on Saturday morning.
No instructions about food intake were given prior to
the medical examination. Lipid profiles were
measured within a few days in the Department of
Chemical Pathology at Hinchingbrooke Hospital, as
part of their standard routine lipid assays. Total
cholesterol, HDL cholesterol, LDL cholesterol and
triglycerides were measured using standard enzy-
matic methods in a fully automated procedure using a
Roche Hitachi 717 analyser with Bio Stat reagents.
Serum cotinine levels were measured using a standard
semi-quantitative microplate enzyme immunoassay
(Cozart Biosciences, Abingdon, UK).
Statistical Analysis
Mean values were compared using a t-test. Multi-
variate analysis was performed using linear regression
methods11 with STATA 5.0 for Macintosh.12 Adjusted
mean PIIINP levels were calculated using logistic
regression models.13 Adjusted means were compared
using Fisher’s F test.
Results
Assessment of collagen turnover in the form of PIIINP
levels was available for 456 subjects. Detailed infor-
mation about medication and PIIINP levels were
available for 420 subjects. Of these 420 subjects, 180
had no evidence of PAOD and no aneurysmal disease,
34 had evidence of PAOD but no aneurysmal disease,
129 had a small aneurysm (30–45 mm diameter) but
no evidence of PAOD, 60 patients had both a small
aneurysm and PAOD and in 17 patients data about
PAOD were missing. They were included in the study.
Thirty-five subjects were on ACE inhibitors and 385
were not. Mean serum PIIINP level was 3.5 mg/l (sd
1.3 mg/l). A large variation in PIIINP levels was found,
range: 1.7–16.5 mg/l. There was a significant increase
in mean collagen turnover between subjects on ACE
inhibitors compared to those not on ACE inhibitors.
Mean PIIINP levels for subject on ACE inhibitors was
4.26 mg/l (95% CI: 3.73–4.79 mg/l), compared to
3.61 mg/l (95% CI: 3.48–3.75 mg/l) for subjects not
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exposed to ACE inhibitors. Mean PIIINP levels of the
36 subjects with missing data about current medi-
cation was 3.78 mg/l (95% CI: 3.30–4.27 mg/l). There
were no statistically significant differences in type III
collagen turnover between subjects on other anti-
hypertensive drugs such as: calcium channel blockers,
diuretics or betablockers (see Table 1). There were no
significant differences in PIIINP levels between sub-
jects with a small aneurysm (mean PIIINP: 3.73 mg/l
95% CI 3.53–3.93) and subjects with a normal aorta
(mean PIIINP: 3.63 mg/l 95% CI 3.47–3.79) (P-value
0.46). There were no significant differences in PIIINP
levels between subjects with evidence of PVD (mean
PIIINP: 3.71 95% CI 3.47–3.95) and subjects with no
evidence of PAOD (mean PIIINP: 3.65 mg/l 95% CI:
3.50–3.80) (P-value 0.71). The difference in collagen
turnover remained significant after adjusting for
presence of aneurysmal disease or evidence of
PAOD. Adjusted mean PIIINP for subjects on ACE
inhibitors was 4.27 mg/l, (95% CI 3.83–4.71 compared
to a mean PIIINP of 3.59 mg/l, (95% CI 3.46–3.73 for
those not on ACE inhibitors (P-value 0.0046).
Stepwise regression was used to investigate which
other variables were associated with PIIINP levels.
Variables investigated were age, height, weight,
systolic and diastolic blood pressure, diabetic status,
smoking status in the form of serum cotinine levels,
and the usual standard lipid risk factors such as: total
cholesterol levels, HDL cholesterol, LDL cholesterol
and triglycerides. Iron is an important cofactor of
collagen metabolism. We also investigated the follow-
ing measurements of iron metabolism: serum iron
levels, transferrin levels, ferritin levels and antic-
hymotrypsine. Stepwise regression showed that
PIIINP levels were significantly associated with age,
height, weight, diastolic blood pressure and ferritin
levels. None of these were significantly different
between subjects on ACE inhibitors and those not on
ACE inhibitors (see Table 2). We calculated adjusted
mean PIIINP levels between subjects exposed to ACE
inhibitors and those not exposed. The difference in
mean PIIINP levels remained significant after adjust-
ing for age, height, weight, HDL and ferritin:
4.14 mcg/l (95% CI: 3.72–4.57 mcg/l) for subjects
exposed to ACE inhibitors versus 3.62 mcg/l (95%
CI: 3.49–3.75 mcg/l) (P-value 0.02).
Discussion
A marked increased type III collagen synthesis, as
measured by PIIINP levels, was seen in subjects on
ACE inhibitors compared to those not exposed to ACE
inhibitors. The difference was highly significant and
remained significant after adjusting for confounding
variables.
Marshall et al.14 recently demonstrated a reduction
in collagen metabolism in lung tissue after adminis-
tration of intratracheal Ramipril (an ACE Inhibitor)
and Losartan (an Angiotensin II type 1 antagonist).
This finding was also noted in their control population
where intratracheal saline was administered. There
was also clear evidence that ACE was not the only
controlling factor for Angiotensin II expression in this
experiment.
Another in vitro experiment,15 this time utilising rat
cardiac cells, investigated the role of N-Acetyl-Seryl-
Aspartyl-Proline (Ac-SDKP), a natural inhibitor of
stem cell entry into S phase (the period for collagen
synthesis).This molecule is hydrolysed by ACE-Is.
They found it to have a biphasic and dose dependant
effect on collagen synthesis. In low doses it had an
inhibitory effect on collagen synthesis, but in high dose
no significant effect was noted.
The use of ACE inhibitors in other animal models of
atherosclerosis has shown a decrease in plaque area
with a decrease in macrophage accumulation. An
increase in the extracellular matrix was also demon-
strated.16 These phenomena could be explained by the
up regulation of collagen synthesis, and the presence
of increased quantities of collagen in the fibrous cap.
Reduced collagen content in the fibrous cap may
result from decreased synthesis of the extra-cellular
matrix by smooth muscle cells (SMCs), increased
breakdown, or both. Vascular SMCs synthesize the
precursors of type III collagen for the extracellular
matrix. The synthesis and degradation of the extra-
cellular matrix proteins are slow in the normal artery.
Atherosclerosis and arterial injury lead to increased
Table 1. Collagen turnover as measured by the serum PIIINP concentration in mcg/l and 95% confidence intervals of the mean between
subjects exposed to classes of antihypertensive drugs and those not exposed. P-values were calculated by applying the t-test to the log
transformation of the mean PIIINP
Drug Number exposed Mean PIIINP and 95% CI Number not exposed Mean PIIINP and 95% CI P-value
ACE inhibitors 35 4.26 (3.73; 4.79) 378 3.62 (3.49; 3.76) 0.007
Ca channel 45 3.53 (3.25; 3.82) 368 3.70 (3.56; 3.84) 0.65
Diuretics 64 3.95 (3.61; 4.30) 349 3.63 (3.49; 3.77) 0.08
Betablockers 77 3.80 (3.52; 4.08) 336 3.65 (3.51; 3.80) 0.25
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synthesis of many matrix components including
collagen type III,16 presumably as part of the response
to the insult.
These results suggest that ACE-I therapy may
increase collagen synthesis, and thus plaque stabilis-
ation. This may provide an alternative explanation for
the decrease in acute vascular events observed in
patients on ACE-I therapy.
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Table 2. Confounding variables associated with PIIINP levels and the differences between subjects on ACE inhibitors and those not
Variable On ACE inhibitors Not on ACE inhibitors P-value
Age 70.7 (68.5–73.1) 70.8 (70.1–71.6) 0.95
Height in cm 172.1 (170.1–174.1) 173.5 (172.8–174.2) 0.24
Weight in kg 81.6 (76.9–86.3) 80.1 (79.0–81.3) 0.49
HDL mmol/l 1.05 (0.95–1.14) 1.16 (1.11–1.21) 0.20
Ferritin mcg/l 136.9 (101.1–172.8) 118.4 (108.4–128.3) 0.29
M. W. Claridge et al.70
Eur J Vasc Endovasc Surg Vol 28, July 2004
